Stock A304840 PEOPLEBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PeopleBio, Inc.

Equities

A304840

KR7304840002

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
2,680 KRW +0.75% Intraday chart for PeopleBio, Inc. +0.56% -12.85%
2023 PeopleBio, Inc. announced that it has received KRW 5.399992647 billion in funding CI
2023 Peoplebio to Raise 5.4 Billion Won From Shares Issuance MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 289,087 182,777 185,487 64,666
Enterprise Value (EV) 1 279,938 157,595 179,176 61,976
P/E ratio -61.1 x -40.2 x -13.5 x -3.18 x
Yield - - - -
Capitalization / Revenue 569 x 317 x 41.7 x 14.5 x
EV / Revenue 551 x 273 x 40.3 x 13.9 x
EV / EBITDA -65.6 x -24.2 x -17.2 x -4.53 x
EV / FCF - 16,042,468 x -13,393,766 x -2,145,306 x
FCF Yield - 0% -0% -0%
Price to Book 16.8 x 11 x 49.2 x 3.44 x
Nbr of stocks (in thousands) 13,091 13,374 14,043 21,029
Reference price 2 22,083 13,667 13,208 3,075
Announcement Date 22-03-18 22-03-18 23-03-20 24-03-21
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 507.9 577.1 4,445 4,453
EBITDA 1 -4,270 -6,501 -10,415 -13,683
EBIT 1 -4,554 -7,236 -11,697 -15,248
Operating Margin -896.78% -1,253.81% -263.16% -342.42%
Earnings before Tax (EBT) 1 -4,383 -4,942 -15,003 -17,382
Net income 1 -4,383 -4,697 -14,303 -16,035
Net margin -863.09% -813.94% -321.79% -360.1%
EPS 2 -361.2 -340.4 -977.7 -967.4
Free Cash Flow - 9,824 -13,378 -28,889
FCF margin - 1,702.28% -300.97% -648.78%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 22-03-18 22-03-18 23-03-20 24-03-21
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 9,149 25,182 6,312 2,690
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 9,824 -13,378 -28,889
ROE (net income / shareholders' equity) - -35.5% -120% -136%
ROA (Net income/ Total Assets) - -14.6% -15.6% -27.3%
Assets 1 - 32,200 91,626 58,804
Book Value Per Share 2 1,314 1,238 268.0 895.0
Cash Flow per Share 2 932.0 2,889 967.0 32.90
Capex 1 158 1,355 1,267 719
Capex / Sales 31.11% 234.77% 28.5% 16.15%
Announcement Date 22-03-18 22-03-18 23-03-20 24-03-21
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
PEOPLEBIO, INC. Stock PeopleBio, Inc.
-12.85% 41.65M
BIOMÉRIEUX Stock bioMérieux
-4.67% 12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-5.19% 8.07B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+9.45% 5.91B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+28.50% 5.52B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-8.09% 4.21B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+13.49% 2.73B
VITROLIFE AB Stock Vitrolife AB
-1.34% 2.43B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+32.24% 2.29B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-3.55% 1.89B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. A304840 Stock
  4. Financials PeopleBio, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW